Merck announces discontinuation of APECS study evaluating verubecestat (MK-8931)
Merck announced it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1, in people with prodromal Alzheimer’s disease. February 13, 2018